Provided by Tiger Trade Technology Pte. Ltd.

Eli Lilly

1,194.90
+37.413.23%
Volume:1.34M
Turnover:1.60B
Market Cap:1.13T
PE:40.11
High:1,206.63
Open:1,172.74
Low:1,166.00
Close:1,157.49
52wk High:1,292.65
52wk Low:783.85
Shares:945.38M
Float Shares:939.00M
Volume Ratio:0.83
T/O Rate:0.14%
Dividend:6.69
Dividend Rate:0.56%
EPS(TTM):29.79
EPS(LYR):22.95
ROE:102.29%
ROA:20.36%
PB:33.34
PE(LYR):52.07

Loading ...

Eli Lilly - Zepbound 10 Mg and 15 Mg Show Comparable Adverse Event Discontinuation Rates to Wegovy Hd

THOMSON REUTERS
·
Sep 29

Eli Lilly - Zepbound 15 Mg Shows 4.5% Greater Weight Loss than Wegovy Hd in Adults with Obesity

THOMSON REUTERS
·
Sep 29

Lilly's Zepbound (Tirzepatide 10 Mg and 15 Mg) was Associated with More Weight Loss than Wegovy Hd (Semaglutide Injection 7.2 Mg) in a New Indirect Treatment Comparison

THOMSON REUTERS
·
Sep 29

Eli Lilly - Zepbound Achieves 20.2% Weight Reduction vs 13.7% for Wegovy at 72 Weeks

THOMSON REUTERS
·
Sep 29

Eli Lilly - Zepbound 15 Mg Users Have over Three Times the Odds of 20% Weight Reduction vs Wegovy Hd

THOMSON REUTERS
·
Sep 29

Lilly Touts Foundayo Advantage over Novo's Ozempic Pill in Diabetes Analysis

Reuters
·
Sep 29

Novo Nordisk Says Ozempic Shows Lower Risk of Cardiovascular Events Compared to Eli Lilly's Mounjaro

Reuters
·
Sep 29

Eli Lilly announces positive results from study of Foundayo 17.2 mg

TIPRANKS
·
Sep 29

Eli Lilly's Foundayo 17.2 Mg was Associated with 1.5% Greater Weight Loss at 52 Weeks

Reuters
·
Sep 29

Lilly Says Foundayo 17.2 Mg Outperforms Oral Semaglutide 25 Mg on Weight Loss, A1C in Indirect Comparison Study

Reuters
·
Sep 29

Eli Lilly - Foundayo 17.2 Mg Shows 1.5% Greater Weight Loss and 0.3% Greater A1c Reduction at 52 Weeks

THOMSON REUTERS
·
Sep 29

$20 Billion In Deals And Counting: Lilly's CEO Targets The "White Space" Of Science For Larger M&A

Options & Short Sell
·
Sep 29

DexCom’s Oura Bet: Potential Investment Gains Meet a Bigger Healthcare Opportunity

Bellwether Stocks Movement
·
Sep 29

Momentum Continues: Lilly Extends Its Lead In The GLP-1 Race

Bellwether Stocks Movement
·
Sep 29

AstraZeneca To Invest $2 Billion In Summit And Co-Develop Drugs; Shares Jump After Hours

Options & Short Sell
·
Sep 29

Sector Update: Healthcare

MT Newswires Live
·
Sep 29

Market Chatter: Eli Lilly CEO Plans Larger Deals to Target New Disease Areas

MT Newswires Live
·
Sep 29

Lilly CEO Eyes Bigger Deals in Hunt for Pharma's 'white Spaces' - Bloomberg News

Reuters
·
Sep 29

Eli Lilly CEO tells Bloomberg sees more deals in untapped areas

TIPRANKS
·
Sep 29

US Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 28